Abstract

Several therapeutic agents for neurological disorders are usually not delivered to the brain owing to the presence of the blood-brain barrier (BBB), a special structure present in the central nervous system (CNS). Focused ultrasound (FUS) combined with microbubbles can reversibly and temporarily open the BBB, enabling the application of various therapeutic agents in patients with neurological disorders. In the past 20 years, many preclinical studies on drug delivery through FUS-mediated BBB opening have been conducted, and the use of this method in clinical applications has recently gained popularity. As the clinical application of FUS-mediated BBB opening expands, it is crucial to understand the molecular and cellular effects of FUS-induced microenvironmental changes in the brain so that the efficacy of treatment can be ensured, and new treatment strategies established. This review describes the latest research trends in FUS-mediated BBB opening, including the biological effects and applications in representative neurological disorders, and suggests future directions.

MeSH

Nervous System Diseases, Therapeutics, Blood-Brain Barrier, Research

Cited by

• Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease. Biomedicines, 2025
• Quantitative Pharmacokinetics Reveal Impact of Lipid Composition on Microbubble and Nanoprogeny Shell Fate. Adv Sci (Weinh), 2024
• A multicellular brain spheroid model for studying the mechanisms and bioeffects of ultrasound-enhanced drug penetration beyond the blood‒brain barrier. Sci Rep, 2024
• Updates on cancer vaccines in brain cancer: Advances in neuroblastoma, delivery systems, and emerging technologies. Hum Vaccin Immunother, 2025
• Glioblastoma Therapy: Past, Present and Future. Int J Mol Sci, 2024